Takeda signs up to $600M AI drug-discovery pact with Insilico

Takeda announced a strategic collaboration with Hong Kong-based Insilico Medicine to apply artificial intelligence across early-stage drug discovery. The agreement gives Takeda exclusive worldwide rights to candidates discovered through Insilico’s platform and could be worth about $600 million if development and sales milestones are achieved.

Under the deal Insilico will lead the AI-driven discovery work using its Pharma.AI suite, while Takeda will advance selected candidates through clinical development and, where chosen, handle manufacturing and global commercialization. The companies did not disclose which therapeutic areas or specific disease targets will be covered.

Pharma.AI comprises tools for target identification, molecule generation and clinical forecasting. The companies identified PandaOmics for target discovery, Chemistry42 for de novo small-molecule design and InClinico for forecasting clinical trial transition probabilities.

The financial package includes roughly $60 million in project initiation fees and near-term payments, with further payments tied to preclinical, clinical, commercial and sales milestones. Insilico is also eligible for tiered royalties on future product sales.

Alex Zhavoronkov, Insilico’s founder and chief executive, noted the proceeds will support early-stage research under the collaboration and said timelines for later-stage work will depend on Takeda’s clinical development activities and coordination between the two companies. Chris Arendt, Takeda’s chief scientific officer and head of research, added the agreement pairs Takeda’s disease biology capabilities with Insilico’s AI discovery tools and that Takeda is integrating automation, robotics and generative AI into its discovery operations.

Insilico previously advanced an AI-generated candidate, rentosertib, a TNIK inhibitor for idiopathic pulmonary fibrosis, into a Phase 2a trial. Earlier this year Takeda also agreed a multi-year collaboration with Iambic worth more than $1.7 billion to design small-molecule drugs. Insilico has disclosed other collaboration agreements with combined potential value in the billions, including expanded work with Eli Lilly and a deal with SK Biopharmaceuticals.

Insilico’s Hong Kong-listed shares rose after the Takeda announcement. The deal provides Takeda exclusive global development, manufacturing and commercialization rights to candidates emerging from Insilico’s platform.